Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Idiopathic Pulmonary Fibrosis (IPF): Update Bulletin [March 2016]

Product Code:
596200559
Publication Date:
March 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in idiopathic pulmonary fibrosis (IPF): Topics covered include opinions about Gilead’s suspension of a Phase II trial of simtuzumab; Boehringer Ingelheim’s initiation of a Phase IV trial combining Esbriet (pirfenidone) with Ofev (nintedanib), as well as views on DS Biopharma’s completion of a Phase I trial of an oral formulation of DS102 (15-HEPE). 

  • How do KOLs view the recent failure of Gilead’s Phase II trial of simtuzumab?
  • Is simtuzumab’s mechanism of action worthy of further investigation for the treatment of IPF?
  • How do KOLs rate the importance of Boehringer Ingelheim’s Phase IV trial combining Esbriet with Ofev for the treatment of IPF?
  • How do KOLs view combining Esbriet with Ofev in terms of gastrointestinal tolerability and pharmacokinetics?
  • Will benefits in terms of efficacy and quality of life justify the high cost of combining Esbriet with Ofev?
  • How likely is it that the combination of Esbriet with Ofev will be used in preference to sequential therapy?
  • In light of recent data, what is the likelihood that an anti-inflammatory molecule, such as DS Biopharma’s DS102, will constitute a successful treatment approach for IPF?



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved